Eltrombopag
Brand: Revolade®
NICE TA: 293
Indication: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (NICE TA293)
Disease category: Nutrition and blood
Commissioning responsibility: CCG
PbR excluded: Yes
Background
Eltrombopag is recommended as an option for treating chronic immune (idiopathic) thrombocytopenic purpura in adults, only if:
• their condition is refractory to standard active treatments and rescue therapies or
• they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies
Eltrombopag is recommended only if the company provides it with the discount agreed in the patient access scheme
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
NICE TA293 - Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |
